Evidence map›Paper›PMID 40810725›Full record

ArticleCancer research communications2025

Loss of Sorting Nexin 10 Accelerates KRAS-Induced Pancreatic Tumorigenesis.

Kohinoor Khan, Mohammad Shameem, Ashley N Sigafoos, Linda Kiey, Catherine E Hagen, Gopal Ramakrishnan, Leslie Morse, Martin E Fernandez-Zapico, Ricardo A Battaglino

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kohinoor KhanDepartment of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-4932-4538
Mohammad ShameemDepartment of Rehabilitation Medicine, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-0578-2622
Ashley N SigafoosDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4237-644X
Linda KieyDepartment of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota.ORCID 0009-0006-8003-3591
Catherine E HagenDivision of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1867-4957
Gopal RamakrishnanTargazyme Inc., Carlsbad, California.ORCID 0000-0001-6033-9370
Leslie MorseDepartment of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-7426-6341
Martin E Fernandez-ZapicoDivision of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8089-3907
Ricardo A BattaglinoDepartment of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-0272-1763

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive forms of pancreatic cancer, is associated with poor survival outcomes and currently ranks as the third leading cause of cancer-related death in the United States. Despite its clinical significance, the mechanisms of PDAC development and progression remain, in part, poorly understood. In this study, we provide evidence of a novel role of sorting nexin 10 (SNX10), a member of the sorting nexin family, in the regulation of KRAS-induced pancreatic carcinogenesis. We demonstrate that SNX10 is downregulated in PDAC, especially in advanced cases. Furthermore, mutational analysis revealed SNX10 genetic alterations in PDAC cases. Functional studies demonstrated that SNX10 overexpression in human PDAC cells inhibited cell proliferation and colony formation. Moreover, SNX10 overexpression induced G1-phase cell-cycle arrest and decreased KRAS signaling activity. Using a novel Snx10 knockout mouse crossed with a Kras-driven PDAC model, we observed reduced survival, increased tumor cell proliferation, enhanced aggression, and heightened inflammation. Collectively, these findings highlight SNX10 as a tumor suppressor candidate in PDAC and underscore its promise as a foundation for new therapeutic approaches. SIGNIFICANCE: SNX10 plays a crucial role in reducing pancreatic tumorigenesis. This discovery offers valuable insights into PDAC's biology and the development of new effective treatments.

Indexed as

CarcinogenesisCarcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Sorting NexinsAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, KnockoutKRAS protein, humanProto-Oncogene Proteins p21(ras)SNX10 protein, humanSorting Nexins

Identifiers

PMID40810725
PMCPMC12415682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.